Eastgate Biotech Corp.
ETBI · OTC
9/30/2017 | 6/30/2017 | 3/31/2017 | 12/31/2016 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | -$0 |
| % Growth | -79.8% | – | 100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | -$0 |
| Gross Profit | -$0 | $0 | $0 | -$0 |
| % Margin | -299.1% | 50.3% | – | 85.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -7,307.8% | -412.6% | – | 756% |
| Other Income/Exp. Net | $0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -7,057.2% | -624.3% | – | 999.2% |
| EPS | -0.002 | -0.001 | -0.003 | -0.003 |
| % Growth | -25% | 60% | 3.2% | – |
| EPS Diluted | -0.002 | -0.001 | -0.003 | -0.003 |
| Weighted Avg Shares Out | 1 | 1 | 0 | 0 |
| Weighted Avg Shares Out Dil | 1 | 1 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | -$0 | $0 | $0 | -$0 |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -7,439.6% | 0% | – | 953.2% |